American pharma company Moderna on Tuesday announced the Phase 2/3 study of its COVID-19 vaccine in adolescents found the vaccine was 100% effective in teens aged 12-17 two weeks after two doses. The study enrolled over 3,700 participants of ages 12 to less than 18 years in the US. The shot was found to be 93% effective after one dose.